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Challenges in the treatment of febrile 
neutropenia 
[s2291 Choice of therapy according to prognostic 
factors and cost issues 
J. Klastersky. Cmfre drs Emeuri de L'CBB, Brussels, Behiurn 
Febrile neutropenia (FN) is a changing syndrome which requires 
periodic updates as our arnianientarium against this condition im- 
proves and the characteristics of the pathogens change. In addition, 
cost of therapy has become a major issue when designing therapeutic 
strategies. The treatmeiit of FN has changed over the past 20 years 
and is \till constantly being re-evaluated in relation to modifications 
of the nature of the offending pathogens, availability of new drugs 
for treatment of infections, and changes in the types of patient who 
become iieutropenic as a consequence of cytostatic therapy. The 
pretent review will deal with recommendations for the treatment of 
FN, with special attention to its cost benefit, and will be based on 
the results of the recently published IATCG-EORTC trials. Costs 
will be evaluated on the basis of the daily expenses for medical care 
of FN in Belgium as they are presently charged to the social security 
services. On the basis of the preceding considerations, an algorithm 
for the treatnient of FN that takes into consideration the cost benefit 
will be proposed as dn incentive to further clinical studies aimed a t  
its validation or rejection. It is recognized, however, that further 
economic analyses should also be based on real-life studies (not 
necessarily on well-controlled, randomized and blinded trials). This 
is relevant for policy-nidkers. 
[s2301 Rational modifications of empirical therapy in 
febrile neutropenia 
B.E. de Pauw. Unir~crsity Hospital St Radboud, Nijmqerz, 
T ~ I P  Ncitherlawds 
Empirical brodspectruni antibiotic therapy has become a generally 
accepted strateb? in the treatment of febrile neutropenic patients. 
Particularly in patients with prolonged neutropenia, subsequent 
adaptation of such a regimen will be the rule rather than the 
exception. Since there are no uniformly accepted guidelines for the 
nioditication of antibiotic therapy during the post-empirical phase, 
we assessed the impact of a set of rules that evolved during the 
conduction of the first randomized trials. Evaluation ofthe clinician's 
compliance with these rules in 1951 febrile neutropenic episodes was 
the subject of the present analysis. Treatment was modified in 761 
(39<!43 cases and these changes were inade according the rules in 76Y.o. 
For 75% of the alterations in treatment during the evening and night 
shifts, 110 reasonable explanation could be established, while 93%) of 
the iiiodificatioris during the normal working hours were inade for 
objective reasons. The empirical regimen was more frequently 
changed in patients with a clinical focus of infection at the onset of 
fever in comparison with patients who showed fever as the only 
symptom of a possible infection. The perceived need for modification 
amounted to 69% in pulmonary infections, to 51% in skin and soft 
tissue infections, to 44?4 in patients with abdominal complaints, and 
to 37% in the upper respiratory tract infections. Glycopeptides 
constituted 21"h of modifications, particularly in patients with a 
central venous catheter, and systemically active antifungals were 
administered in 16"h of cases. Especially inexperienced clinicians tend 
to adjust antibiotic therapy in spite of the fact that persistence of fever 
alone seldom reflects inadequate treatment when the clinical 
condition of the patient is stable or improving. On the other hand, 
the development of subsequent infectious events emphasizes that a 
genuine need for modification does frequently exist. 
Is2311 Indications for bone marrow-stimulating or - 
protecting agents 
G. Maschmeyer. Cltaritr University Hospiful, Roberr Rocssle Cuiinr 
Cenrcr, Berlin, Germany 
The curative potential of intensive antineoplastic chemotherapy is 
limited by treatment- induced toxicity, predominantly by severe and 
prolonged myelosuppression as we11 as mucosal damage, both result- 
ing in serious and life-threatening infections. The advent of rcconi- 
binant heniatopoietic growth factors such as granulocyte colony- 
stimulating factor (G-CSF), granulocyte-macrophage colony-stiniu- 
lating fdctor (GM-CSF) and, recently, also stem cell factor (SCF), 
interleukin-3, interleukin-1 1 and thronibopoietin (TPO) or mrga- 
karyocyte growth and development factor (MGDF) has opened new 
perspectives for a marked reduction of chemotherapy-induced 
neutropenia and throinbopenia. Prospective, randomized clinical 
trials have demonstrated a significant decrease in the incidence of 
infections as well as a shortening of hospitalization by prophylactic 
administration of G-CSF or GM-CSF post-chemotherapy, and this 
prophylactic use is recommended in patient7 in whom febrile 
complications during neutropenia are expected with more than 40% 
probability. In patients with serious life-threatening infections who 
are not receiving G-CSF or GM-CSF prophylactically, interventional 
application may be useful in individual cases. The thiophosphate 
prodrug amifostine may reduce mucosal and bone iiiarrow toxicity 
from cherno/rddiothrrapy and has shown some clinical benefit in 
solid tumor patients without significant impairment of anticancer 
treatment efficacy Its usefulness in patients with high-grade 
inalignant henidtologic diseases, however, has not been demonstrated 
so far. 
1-1 Costs and benefits of various approaches to 
the febrile neutropenic patient 
F. Menichetti. Instilulo Afclttie Itzfictive, Policlinico hlontelme, Pcrqia, 
I1aly 
The strategies for cost containment in the management of febrile 
neutroprnia are represented by the control of the ceverity and dura- 
tion of neutropenid with colony-stimulating factors, the reduction of 
the hospitalization period with home or ambulatory care, and the 
choice of the most cost-effective empirical antibiotic regimen. 
Several alternatives to hospital-based therapy have been evaluated in 
low-risk neutropenic patients: early ditcharge to home antibiotic 
therapy or treatment of the entire febrile episode with intravenous or 
oral antibiotics in the atnbulatory setting or at home. Monotherapy 
(i.e. oral fluoroquinolones, once-daily third-generation cephalo- 
sporins) can be used, depending on local epidemiology. The 
approach to high-risk neutropenic patients is represented by hos- 
pitalization and prompt institution of empirical antibiotic therapy. 
Cost-efficacy analysis should be planned to prospectively identify the 
tnost effective and less costly regimen. Cost-mininiization analysis is 
able to compare the costs of two equally effective regimens. The 
elements useful for evaluating the economic impact of the empirical 
antibiotic regimens are represented by the cost of therapy (drug 
acquisition cost and administration cost, including nursing time and 
the materials), the cost of failure and the cost of the adverse events 
(drug acquisition cost, administration cost and cost of diagnostic 
evaluation). The comparative analysis of the acquisition cost of several 
empirical antibiotic regimens validated in R C T  indicates that 
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the combination of ceftriaxone and amikacin is less costly than 
ceftazidime plus amikacin, piperacillin/tazobactam plus amikacin, 
and meropeneni. However, it should be stressed that the choice of 
antibiotic regimen should be based primarily on clinical and 
epidemiologic considerations; that is, in a setting of high risk of 
Pseudomonas aeruginosa infections, an antipseudomonal beta-lactam 
antibiotic should be preferred. 
New aspects of cystic fibrosis, lung infection 
and inflammation 
Defensins in cystic fibrosis (CF) 
J.-M. Schroeder. Department gDermatology, University o f  Kiel, Kiel, 
Germany 
Because Pseudomonas aeruginosa represents an imminent threat to 
patients with CF but not healthy persons, we addressed the question 
what keeps normal lungs fkee of I! aeruginora infection. Based on the 
working hypothesis that lung epithelial cells secrete I! aeruginosa 
killing peptide antibiotics, we isolated from supernatants of I? 
aeruginosa-stimulated lung epithelium cell line US49 a 4-kDa I? 
ueruginosa killing peptide, which is identical to human O-defensin 2 
(hBD-2), a defensin we recently discovered in inflamed skin. Natural 
hBD-2 strongly killed I? aeruginora (LDy":lOmg/L), but not 
Staphylococcus aureus (growth inhibition at concentration 100 mg/L). 
In contrast to all known human defensins, hBD-2 synthesis is 
inducible in epithelial cells by contact with bacteria or pro- 
inflammatory cytokines, which is supported by analyses of the 
promoter region of the hBD-2 gene. Because in CF it is believed that 
increased NaCI concentrations may affect antimicrobial activity of 
endogenous peptide antibiotics, we investigated the salt sensitivity of 
hBD-2 and found a dose-dependent inhibition of I? aeruginosa killing 
activity (I&: -80 mM), inmcating that hBD-2 is salt sensitive at 
physiologic ion strength. Investigation for hBD-2 in sputum of CF 
patients revealed immunoreactive hBD-2, indicating that hBD-2 
production is not defective in CF. Systematic screening of CF 
patients' sputum for antimicrobial activity, however, revealed-apart 
from known defensins 1-3 and lysozyme-a number of as yet not 
identified molecules that might be important in antimicrobial defense 
in CF. 
Epithelial cell interactions involving CFTR and 
bacterial pathogens 
G. Pier. Hurvard Medical School, Channing Laboratory, Boston, MA, 
USA 
The CF transmembrane conductance regulator (CFTR) plays a 
critical role a$ a receptor involved in the lung's response to Pseudo- 
moms aeruginosa. The absence of CFTR protein in most severe cases 
of CF results in decreased clearance of I! aeruginosa from the lung in 
the early stages of infection. We have recently determined that under 
the right conditions CF mice are hypersusceptible to oropharyngeal 
colonization by I! aeruginora from environmental sources as well as 
experimentally induced I? aeruginora lung infection. All mice exposed 
to I) aeruginosa in drinking water become colonized in the 
oropharynx, but once the contaminated water is removed, both wild- 
type and heterozygote *F508 Cftr mice clear the colonization, 
whereas CF mice remain colonized for prolonged periods. Intro- 
duction of I) aeruginosa enmeshed in alginate beads into the lungs of 
CF mice results in long-term infection accompanied by significant 
changes in pulmonary obstruction, whereas mice with at least one 
wild-type Cftr gene clear this infection. CFTR is also utilized by 
Salmonella typhi as a receptor for translocation from the gastro- 
intestinal tract. Recent stumes in CF mice with a G551 D allele 
indicate that this Cftr mutation results in decreased uptake of both S. 
typhi and I? aeruginosa by homozygote G551 D and heterozygote 
G551 D mice compared with wild-type mice. This is identical to 
results reported for *F508 Cftr mice. Overall, CFTR is an important 
receptor for both I? aeruginosa and S. typhi, and changes in CFTR 
protein due to mfferent gene mutations can result in a similar pheno- 
type in regard to susceptibility and resistance to I? aeruginosa and S. 
typhi infections. 
Neutrophil-parasite interactions 
N. Hoiby. Department of Clinical Microbiology 9301 G Danish Cystic 
Fibrosis Center, Copenhagen, Denmark 
Most patients with cystic fibrosis (CF) suffer from chronic endo- 
bronchial Pseudomonas aeruginosa infections. The lung tissue damage 
is caused by continuous activation of the immunologically specific 
inflammatory defense mechanisms of the lungs initiated by the anti- 
body response and dominated by polymorphonuclear neutrophil 
leukocytes and their proteolytic and oxidative products. This inflam- 
mation induces a phenotypic shift from non-mucoid to mucoid, 
alginate-producing phenotypes of I! aeruginosa which then grow as a 
biofilm endobronchially. Such biofilms are impossible to eradicate 
with antibiotics. Currently used treatment strategies are chronic 
suppressive antibiotic treatment against I! aeruginora and use of anti- 
inflammatory drugs such as inhaled budesonide or systemic treatment 
with ibuprofen or piroxicam. The immune response responsible for 
the tissue damage mimics a Th2 response, and animal experiments 
suggest that a shift to a Thl-like response by, for example, gamma- 
interferon treatment, may delay the tissue damage. Clinical trials have, 
however, not yet been carried out with gamma-intexferon treatment. 
182421 Bacterial vaccines in cystic fibrosis 
G. Doering. Hygiene-Institute, University of Tuebingen, Tuebingen, 
Germany 
In patients with cystic fibrosis (CF), Preudomonas aeruginosa and 
Staphylococcus aureus cause chronic pulmonary infections which are 
difficult to treat with antibiotics. Loss of lung function is the major 
cause of death in CF. Vaccination is a possible way to prevent these 
infections, and several antigens, including I? aeruginosa flagella and S. 
aureus exopolysaccharides, are promising vaccine candidates. In vitro 
and animal studies showed that flagella antigens were protective in 
compromised animals. Phase 1 studies using Immuno s flagella 
vaccines in healthy individuals and CF patients revealed that these 
vaccine preparations were well tolerated, showed no adverse side 
effects and gave rise to high and long-lasting antibody titers in the 
circulation of the individuals. Furthermore, immunization with a 
flagella vaccine elicited specific anti-flagellar antibodies not only 
systemically, but also in the secretory immune system of the airways. 
Consequently, a phase Ill multicenter vaccine trial using the I? 
aeruginosa 5142/1210-Flagella Vaccine IMMUNO was initiated. The 
study design is placebo-controlled, randomized and double-blind, 
involving about 500 CF patients without I? aeruginosa lung infection 
in 25 European CF centers. 
